MLSS News & Events

Milestone Scientific announced the launch of the CompuFlo Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders to generate a targeted 1,000-2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT code 0777T from Category III to Category I status, that could enhance commercial adoption and long-term revenue visibility.

Milestone Scientific announced the launch of The Wand Ambassador Program, a scalable peer-to-peer engagement initiative designed to expand clinical awareness, education, and adoption of The Wand STA System within the dental market. The program leverages experienced dental professionals to share real-world clinical insights, workflow considerations, and firsthand experiences with colleagues. This peer-driven approach is intended to increase high-quality engagement with prospective practices and encourage direct interaction with Milestone for product demonstrations, training, and deeper evaluation of the clinical and operational benefits of The Wand STA system. The Ambassador Program pilot launched on December 8 with six registered dental professionals in select U.S. markets. Milestone reports early positive feedback from the pilot group and strong inbound interest from additional practitioners seeking to participate, reinforcing management's confidence in the program's scalability and relevance. Milestone plans to expand the program to approximately 250 dental professionals over the next 12 months, supported by a structured onboarding and education framework, centralized learning resources, and defined pathways that connect interested practices with Milestone's commercial and clinical support teams. Internal program tools provide real-time visibility into engagement activity, enabling the company to measure effectiveness, optimize execution, and scale efficiently. Based on early pilot activity and historical performance metrics, Milestone expects the Ambassador Program-combined with an increased focus on new and emerging social media channels-to drive approximately 2-3x growth in product demonstrations, supporting more informed evaluations and contributing to stronger demo-to-sales conversion efficiency over time.

Milestone Scientific provided a business update highlighting the Company's transformation and growth initiatives under the leadership of its new CEO Eric Hines. Since joining Milestone Scientific two months ago, Mr. Hines has conducted a comprehensive review of the Company's operations and implemented a series of strategic actions designed to accelerate growth, strengthen its competitive position, and improve operating efficiency. Actions within the dental segment include expanding the Company's North American sales programs and increasing the focus on direct sales opportunities; streamlining and expanding omnichannel digital marketing to increase brand awareness; and securing new international registrations for the STA Single Tooth Anesthesia System. The Company plans to utilize a similar strategy for its medical segment, including a guided relaunch of CompuFlo. In addition, the Company is investing in specialized market analysis and reimbursement strategies to maximize the commercial potential of the Company's CompuFlo technology in healthcare settings. Lastly, the Company is instituting broad-based reductions in operating expenses across the organization. "We have taken strong, decisive steps over the past two months to align Milestone Scientific for the next phase of growth," stated Hines. "Through a top-to-bottom analysis of the business, we have identified significant opportunities for improvement and begun executing initiatives to capture them. Notably, during the third quarter, we reduced our operating expenses by approximately 20% compared to the same period in 2024, while achieving modest revenue growth and seeing an uptick in recurring revenue from the CompuFlo disposables, even before fully implementing our new sales and marketing initiatives. We are also observing strong interest in CompuFlo internationally. Although we have been relatively quiet publicly, there is a significant amount of activity taking place behind the scenes that we believe will strengthen both our medical and dental segments and enhance the Company's financial performance. We remain committed to advancing our innovative technology, expanding our market presence, and executing on our pipeline of new products and partnerships. The steps we are taking now - from strengthening our sales infrastructure to optimizing our operations - provide a strong foundation for sustained growth and profitability. I could not be more encouraged by the outlook for the business and look forward to sharing updates on our progress."